-+ 0.00%
-+ 0.00%
-+ 0.00%

Missed Pfizer's Rally? Here Is What Holders Saw

Simply Wall St·11/19/2026 16:08:06
Listen to the news

If Pfizer sat on your watchlist instead of in your portfolio, the outcome over the past year may feel like a missed call. For Pfizer shareholders, the return over the past year was 20.3%, including dividends. Analysts were split in late 2025, with one camp leaning on oncology expansion and emerging markets, and another warning that regulation and patent loss would bite. If you rewind to that disagreement, which side of the patent cliff argument would have guided your own decision?

This theme extends beyond Pfizer. See which of 37 healthcare AI stocks may still merit a closer look.

The Two Pfizer Stories Investors Had To Weigh

The shares cost US$25.45 at the start of the period, and you were basically choosing between two stories about where Pfizer might head next.

On the bullish side, one camp argued that cancer drugs and vaccines would do the heavy lifting, with a Fair Value of US$28.77. This was a price level their assumptions implied, built on a late stage pipeline in oncology and rare diseases plus expansion in emerging markets.

The bearish view put more weight on pricing pressure and patent expiries, with a Fair Value of US$23.58. This rested on drug price negotiations and a revenue decline of 4.2% a year as key risks.

NYSE:PFE 1-Year Stock Price Chart
NYSE:PFE 1-Year Stock Price Chart

What The Evidence Did To The Pfizer Thesis

FDA approvals for Ibrance, Tukysa, Talzenna plus Xtandi, and the PADCEV Keytruda combo all pushed Pfizer further into oncology, which lined up with the bullish story. Earnings evidence pulled the other way. Q3 2026 revenue slipped slightly from US$16,654m to US$16,583m, net income eased from US$3,541m to US$3,242m, and net margin fell from 21.3% to 19.6%. The period cut both ways.

The key assumption investors had to test was whether new oncology and obesity products could offset pricing pressure and patent losses. For any other healthcare stock, it would be important to match that claim directly against segment revenue trends, reported margin movement, and the timing of major loss of exclusivity.

What Pfizer's Recent Gain Already Assumes

Pfizer shares trade at US$28.06 after a 20.3% gain over the past year, while the bearish analyst Narrative on Simply Wall St places its Fair Value below that level. That view leans on pressure from pricing reforms, regulation, and patent expiries, alongside the recent impairment charges.

A buyer today effectively banks on obesity, oncology, and cost savings plans supporting future earnings. The key question is how the execution risks flagged in that Narrative affect the odds of that playing out.

"The current numbers imply Pfizer's share price already reflects successful execution on cost savings and pipeline delivery, leaving limited room for error if any of these pillars underperform."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Looking Beyond Pfizer's Pipeline

Pfizer frames one version of the healthcare bet you might make. A step sideways asks how other drug makers tackle similar problems.

One rival leans on vaccines and specialty treatments, especially in cancer and immune disorders. Its pitch rests on turning a deeper late stage pipeline into real prescriptions.

To support that, the business develops long acting injectable therapies for HIV and liver disease. It is also rebuilding R&D around data, AI and faster targeted trials.

Adult vaccines form the other leg, with programs exploring wider health benefits beyond infection prevention. If that effort succeeds, your shortlist of Pfizer peers may look different.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 17% above its price